We have discovered seven novel 12-membered macrolides, pladienolides A to G, from Streptomyces platensis Mer-11107, with pladienolide B the most potently inhibiting hypoxia induced-VEGF expression and proliferation of the U251 cancer cell line. A growth inhibitory study using a 39-cell line drug-screening panel demonstrated that pladienolide B has strong antitumor activities in vitro. A COMPARE analysis reveals that it has a unique antitumor spectrum that sets it apart from anticancer drugs currently in clinical use. This result suggests that pladienolide B has a novel mechanism of action. A series of xenograft studies were conducted to evaluate the in vivo potency of pladienolides. Pladienolide B extensively inhibited tumor growth in xenograft models. In the most sensitive model, using BSY-1 xenografts, tumors were completely regressed by administration of pladienolide B. For the reason of their novel mechanism of action and excellent in vivo efficacy, pladienolides appear to have major potential for use in cancer treatment.
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Tumor cells are frequently exposed to severe hypoxia. To survive and grow under hypoxic conditions, tumors adapt to their environment by activating a series of cascading events.
This opens the possibility of creating novel antitumor drugs that interfere with the signaling involved in these adaptation processes. One key regulator for hypoxia adaptation is known to be hypoxia-inducible factor-1 (HIF-1)1). HIF-1 is an essential transcription factor and is composed of two basic helix-loop-helix (HLH) PAS transcription subunits, as targets for antitumor drug development2,3). However, it is difficult for small molecules to inhibit HIF-1 directly, since it is an HLH transcription factor. Accordingly, several groups are searching for compounds that inhibit the HIF-1 pathway, using a reporter gene assay controlled by hypoxiaresponsive element (HRE), an HIF-1 binding sequence4).
We also have developed a cell-base screening system using VEGF promoter (2.3kb) containing endogenous HRE to search for HIF pathway modulators. The system is based on genetically engineered U251 human glioma cells that stably express a recombinant vector in which the placental alkaline phosphatase (PLAP) reporter gene is placed under the control of the human VEGF promoter. We performed a high throughput screening and as a result identified a series of microbial products that inhibit hypoxia-induced PLAP expression5). They are structurally novel 12-membered macrolides, which we designate as pladienolides5, 6) In this report, we describe the in vitro and in vivo antitumor activities of pladienolides. These substances show highly potent antitumor activity both in vitro and in vivo, and may thus have potential for use in anticancer therapy.
Materials and Methods

Antitumor Agents
Pladienolides B, C, and D were purified at Eisai Co., Ltd.
(Tsukuba Research Laboratories, Ibaraki, Japan); they are shown in Fig. 1 In Vivo Antitumor Activities Female or male BALB/c nu/nu mice (7 weeks of age;
Clea Japan, Inc., Tokyo, Japan) were housed in barrier facilities on a 12-hour light/dark cycle, with food and The effect of growth inhibition of pladienolide B on several anticancer drug-resistant cell lines was measured (Table 2) (Fig. 3B) . We then examined pladienolide B against six human tumor xenografts at doses of 2.5, 5, and 10mg/kg/day in nude mice. Pladienolide B showed strong growth inhibitory or regressive activities against these xenografts (Fig. 4) .
In the BSY-1 xenograft model, the administration of pladienolide B at doses of 2.5, 5, and 10mg/kg/day completely regressed the BSY-1 tumor at Day 15 after the first administration. To observe tumor recurrence, mice were monitored for more than three months, and only one (Fig. 4) . 
